Menu
The new sharewise is here Clearer, faster, with a light and a dark view — and everything you already know. Try it now
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Pfizer Stock a Buy?


Last Tuesday, pharmaceutical titan Pfizer (NYSE: PFE) reported its 2019 fourth-quarter earnings. This underwhelming Q4 report -- in conjunction with the downturn in the broader markets due to the coronavirus threat -- have caused the drugmaker's shares to dip by nearly 7% so far this week.

While Pfizer's year-end results were certainly nothing to write home about, it's still fairly rare for a megacap pharma company to fall by high single-digits in just a matter of two trading sessions. Should investors take advantage of this profound weakness, or is this hefty sell-off justified? Let's break down Pfizer's near-term prospects to find out. 

Image source: Getty Images.

Continue reading


Source Fool.com

Like: 0
PFE
Share

Comments